Spots Global Cancer Trial Database for nsclc stage iv

Every month we try and update this database with for nsclc stage iv cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)	NCT05429320	Non-small Cell ... Metastatic Non ... Nsclc NSCLC Stage IV Minimal Residua... Non Small Cell ...	Local ablative ... Blood collectio...	18 Years -	Memorial Sloan Kettering Cancer Center
PD-L1 PET Imaging in Patients With the Immunotherapy for Non-small Cell Lung Cancer	NCT05533086	NSCLC Stage IV PD-L1 Gene Ampl...		18 Years -	Tongji Hospital
SRS Sequential Sindilimab in Brain Metastasis of NSLSC	NCT04180501	NSCLC Stage IV Brain Metastase... SRS Sintilimab	SRS sequential ...	18 Years - 70 Years	Wuhan Union Hospital, China
Phase 2 Study of Dacomitinib in NSCLC	NCT04027647	NSCLC Stage III... NSCLC Stage III... NSCLC Stage IV Recurrent NSCLC EGFR Positive N...	Dacomitinib	18 Years -	National Cancer Centre, Singapore
Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC	NCT04507906	NSCLC Stage IV Checkpoint Inhi...	Nivolumab Combi...	18 Years - 75 Years	Shanghai Chest Hospital
Factors Determining the Prognosis in NSCLC Stage IV	NCT04306094	NSCLC Stage IV		18 Years -	Instituto do Cancer do Estado de São Paulo
Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2	NCT04604470	NSCLC Stage IV Lung Cancer Non Small Cell ... Metastatic Canc...	Decision tool	18 Years -	Maastricht University
EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide	NCT03341494	NSCLC Stage IV Chemotherapy Ef...	Thalidomide	18 Years - 70 Years	Fujian Cancer Hospital
Prophylactic Peptide Vaccine in Advanced ALK+ NSCLC	NCT05950139	NSCLC Stage IV ALK Fusion Prot...	Peptide vaccine	18 Years -	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prophylactic Peptide Vaccine in Advanced ALK+ NSCLC	NCT05950139	NSCLC Stage IV ALK Fusion Prot...	Peptide vaccine	18 Years -	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Camrelizumab Combined With Local Treatment in NSCLC Patients With BM	NCT04291092	NSCLC Stage IV Brain Metastase... Immunotherapy	Immunotherapy WBRT Chemotherapy	18 Years -	Zhejiang Cancer Hospital
AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)	NCT04364620	NSCLC Stage IV	AB-16B5 Docetaxel	18 Years -	Alethia Biotherapeutics
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC	NCT04467723	NSCLC Stage IV NSCLC, Recurren...	Atezolizumab	18 Years -	University of Kansas Medical Center
To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC	NCT03130829	NSCLC Stage IV NSCLC, Stage II...	Oligo Fucoidan Placebo	20 Years -	Hi-Q Marine Biotech International, Ltd.
TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV	NCT01674738	Carcinoma, Non-...	Pemetrexed Cisplatin Bevacizumab	18 Years - 70 Years	Aktion Bronchialkarzinom e.V.
Phase I Study of SPH1188-11 in NSCLC	NCT03231475	NSCLC Stage III... NSCLC Stage IV	SPH1188-11	18 Years - 70 Years	Shanghai Pharmaceuticals Holding Co., Ltd
SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC	NCT04106180	NSCLC Stage IV	GM-CSF Sintilimab SBRT	18 Years -	Fudan University
Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer	NCT03713944	NSCLC Stage IV NSCLC, Recurren...	Carboplatin Pemetrexed Atezolizumab Bevacizumab	18 Years -	Big Ten Cancer Research Consortium
A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC	NCT05212922	HCC NSCLC Stage III... NSCLC Stage IV	YH001 + Toripal...	18 Years -	Eucure (Beijing) Biopharma Co., Ltd
Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy	NCT04613804	NSCLC Stage IV	Toripalimab Inj...	18 Years - 75 Years	Fujian Cancer Hospital
SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors	NCT05387044	NSCLC Stage IV	SBRT	18 Years -	Zhejiang Cancer Hospital
Plasma-Adapted First-Line Pembro In NSCLC	NCT04166487	NSCLC Stage IV Metastatic Non-...	Pembrolizumab PEMETREXED CARBOPLATIN PACLITAXEL InVision	18 Years -	Dana-Farber Cancer Institute
EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide	NCT03341494	NSCLC Stage IV Chemotherapy Ef...	Thalidomide	18 Years - 70 Years	Fujian Cancer Hospital
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC	NCT05332925	Lung Cancer NSCLC NSCLC Stage IV	Standard of car...	18 Years - 110 Years	University of Kansas Medical Center
A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC	NCT04521075	Melanoma Stage ... Unresectable Me... NSCLC Stage IV	Fecal Microbial...	18 Years -	Ella Therapeutics Ltd
Phase I Study of SPH1188-11 in NSCLC	NCT03231475	NSCLC Stage III... NSCLC Stage IV	SPH1188-11	18 Years - 70 Years	Shanghai Pharmaceuticals Holding Co., Ltd
TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV	NCT01674738	Carcinoma, Non-...	Pemetrexed Cisplatin Bevacizumab	18 Years - 70 Years	Aktion Bronchialkarzinom e.V.
Prospective Observation of Failure Patterns in NSCLC Treated With ICIs	NCT04492969	NSCLC Stage IV NSCLC, Recurren...		18 Years - 75 Years	Fudan University
PD-L1 PET Imaging in Patients With the Immunotherapy for Non-small Cell Lung Cancer	NCT05533086	NSCLC Stage IV PD-L1 Gene Ampl...		18 Years -	Tongji Hospital
Lung Cancer Registry	NCT04654364	Lung Cancer NSCLC Stage IV NSCLC, Stage II... SCLC, Extensive... SCLC, Limited S...		18 Years -	Arbeitsgemeinschaft medikamentoese Tumortherapie
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC	NCT03184571	Lung Cancer Met... NSCLC Stage IV Adenocarcinoma ...	Bemcentinib; pe...	18 Years -	BerGenBio ASA
Neo-MASCT Immunotherapy for Advanced NSCLC.	NCT03205930	NSCLC Stage IV	Neo-MASCT	18 Years - 80 Years	The First People's Hospital of Lianyungang
Additional Chemotherapy for EGFRm Patients With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)	NCT05281406	NSCLC Stage III... NSCLC Stage IV	Osimertinib Pemetrexed Cisplatin Carboplatin	18 Years -	Goethe University
Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients	NCT04076228	NSCLC Stage IV	Pembrolizumab	18 Years - 80 Years	Kiang Wu Hospital
An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1)	NCT01684111	Carcinoma, Non-...	BIBF 1120 Vinorelbine	71 Years -	Aktion Bronchialkarzinom e.V.
A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC	NCT05212922	HCC NSCLC Stage III... NSCLC Stage IV	YH001 + Toripal...	18 Years -	Eucure (Beijing) Biopharma Co., Ltd
1st Line Durvalumab in PS 2 NSCLC Patients	NCT03620669	NSCLC Stage IV NSCLC Stage III...	Durvalumab	18 Years -	Swiss Group for Clinical Cancer Research
Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)	NCT04636775	NSCLC Stage IV NSCLC, Recurren...	Microbiome	18 Years -	University of Kansas Medical Center
A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC	NCT04521075	Melanoma Stage ... Unresectable Me... NSCLC Stage IV	Fecal Microbial...	18 Years -	Ella Therapeutics Ltd
Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy	NCT04613804	NSCLC Stage IV	Toripalimab Inj...	18 Years - 75 Years	Fujian Cancer Hospital
Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors	NCT03647956	NSCLC Stage III... NSCLC Stage IV EGFR Activating...	Atezolizumab Bevacizumab Carboplatin Pemetrexed	18 Years -	The University of Hong Kong
Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)	NCT05816499	NSCLC Stage IV NSCLC Stage III... NSCLC Stage III...	Cadonilimab Anlotinib Docetaxel	18 Years -	Shanghai Chest Hospital
IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study	NCT03705403	NSCLC Stage IV Metastatic Dise...	Darleukin Radiation	18 Years -	Maastricht University Medical Center
Study of AGEN1884 With Pembrolizumab in 1L NSCLC	NCT03411473	NSCLC Stage IV	AGEN1884 in com...	18 Years -	Agenus Inc.
A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients	NCT05787613	NSCLC Stage IV	HLX26 Serplulimab Chemotherapy dr... Placebo	18 Years - 75 Years	Shanghai Henlius Biotech
Genomic Study in Non-small Cell Lung Cancer Brain Metastasis	NCT04745715	NSCLC Stage IV Brain Metastase...	craniectomy	-	National Cheng-Kung University Hospital
A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC	NCT05212922	HCC NSCLC Stage III... NSCLC Stage IV	YH001 + Toripal...	18 Years -	Eucure (Beijing) Biopharma Co., Ltd
Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer	NCT03713944	NSCLC Stage IV NSCLC, Recurren...	Carboplatin Pemetrexed Atezolizumab Bevacizumab	18 Years -	Big Ten Cancer Research Consortium
1st Line Durvalumab in PS 2 NSCLC Patients	NCT03620669	NSCLC Stage IV NSCLC Stage III...	Durvalumab	18 Years -	Swiss Group for Clinical Cancer Research
A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies	NCT04042558	NSCLC Stage III... NSCLC Stage IV EGFR Gene Mutat... ALK Gene Rearra... ROS1 Gene Mutat...	Carboplatin + P... Carboplatin + P...	18 Years - 75 Years	Centre Francois Baclesse
Camrelizumab Combined With Local Treatment in NSCLC Patients With BM	NCT04291092	NSCLC Stage IV Brain Metastase... Immunotherapy	Immunotherapy WBRT Chemotherapy	18 Years -	Zhejiang Cancer Hospital
Comparison of Genomic and Transcriptomic Patterns Between CTC and Metastatic Tumormetastatic Tumor	NCT04932343	NSCLC Stage IV NSCLC Stage III...	cohort study	-	Samsung Medical Center
A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)	NCT05859217	Lung Cancer NSCLC Stage IV Metastatic NSCL... Advanced NSCLC	Cabozantinib Atezolizumab	18 Years -	University of Kansas Medical Center
TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV	NCT01674738	Carcinoma, Non-...	Pemetrexed Cisplatin Bevacizumab	18 Years - 70 Years	Aktion Bronchialkarzinom e.V.
An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2)	NCT01683682	Carcinoma, Non-...	BIBF 1120 Vinorelbine Carboplatin	71 Years -	Aktion Bronchialkarzinom e.V.
Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC	NCT04507217	NSCLC Stage IV Brain Metastase... PD-1 Antibody	Tislelizumab, C...	18 Years - 75 Years	Sun Yat-sen University
Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status	NCT05673187	NSCLC Stage IV KRAS P.G12C	Adagrasib	18 Years -	ETOP IBCSG Partners Foundation
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC	NCT04136535	NSCLC Stage IV	Pemetrexed Carboplatin Anlotinib	18 Years - 75 Years	Fudan University
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC	NCT03184571	Lung Cancer Met... NSCLC Stage IV Adenocarcinoma ...	Bemcentinib; pe...	18 Years -	BerGenBio ASA
Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC	NCT05691829	NSCLC Stage IV	Pembrolizumab Radiation Chemotherapy	18 Years - 100 Years	NYU Langone Health
Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients	NCT04223596	Lung Cancer NSCLC NSCLC Stage III... NSCLC Stage IV	Brigatinib	18 Years -	Fundación GECP
HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC	NCT06218940	NSCLC Stage IV	HY1272	18 Years - 65 Years	Newsoara Biopharma Co., Ltd.
FGFR Inhibitor in FGFR Dysregulated Cancer	NCT03827850	Lung Cancer NSCLC Pulmonary Neopl... Squamous Cell L... NSCLC Stage IV	ERDAFITINIB	18 Years -	Lung Cancer Group Cologne
HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC	NCT06218940	NSCLC Stage IV	HY1272	18 Years - 65 Years	Newsoara Biopharma Co., Ltd.
FGFR Inhibitor in FGFR Dysregulated Cancer	NCT03827850	Lung Cancer NSCLC Pulmonary Neopl... Squamous Cell L... NSCLC Stage IV	ERDAFITINIB	18 Years -	Lung Cancer Group Cologne
Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC	NCT04507906	NSCLC Stage IV Checkpoint Inhi...	Nivolumab Combi...	18 Years - 75 Years	Shanghai Chest Hospital
PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC	NCT04284202	NSCLC Stage IV ARID1A PD-1	PD-1 plus Dasat...	18 Years -	The Affiliated Hospital of Qingdao University
Donation of Post Mortem Tumor Tissues	NCT03385980	NSCLC Stage IV CRC CUP	Proteomic analy...	-	Niguarda Hospital
Lung Cancer Registry	NCT04654364	Lung Cancer NSCLC Stage IV NSCLC, Stage II... SCLC, Extensive... SCLC, Limited S...		18 Years -	Arbeitsgemeinschaft medikamentoese Tumortherapie
An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1)	NCT01684111	Carcinoma, Non-...	BIBF 1120 Vinorelbine	71 Years -	Aktion Bronchialkarzinom e.V.
Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients	NCT04223596	Lung Cancer NSCLC NSCLC Stage III... NSCLC Stage IV	Brigatinib	18 Years -	Fundación GECP
Safety and Potential Efficacy of MS-20 In Combination With Pembrolizumab for the Treatment of NSCLC	NCT04909034	NSCLC Stage IV	MS-20 Placebo	20 Years -	Microbio Co Ltd
Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC	NCT05055583	NSCLC Stage IV Oligometastasis	Toripalimab in ... Surgical treatm... Adjuvant treatm...	18 Years - 70 Years	Tang-Du Hospital
Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2	NCT04604470	NSCLC Stage IV Lung Cancer Non Small Cell ... Metastatic Canc...	Decision tool	18 Years -	Maastricht University
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC	NCT04136535	NSCLC Stage IV	Pemetrexed Carboplatin Anlotinib	18 Years - 75 Years	Fudan University
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC	NCT05543330	Malignant Pleur... NSCLC Stage IV	M701 pleural in... Pleural drainag... Cisplatin pleur...	18 Years - 75 Years	Wuhan YZY Biopharma Co., Ltd.
Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC	NCT05691829	NSCLC Stage IV	Pembrolizumab Radiation Chemotherapy	18 Years - 100 Years	NYU Langone Health
Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC	NCT06219317	NSCLC Stage IV	Cemiplimab Placebo	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study	NCT03705403	NSCLC Stage IV Metastatic Dise...	Darleukin Radiation	18 Years -	Maastricht University Medical Center
A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)	NCT05429320	Non-small Cell ... Metastatic Non ... Nsclc NSCLC Stage IV Minimal Residua... Non Small Cell ...	Local ablative ... Blood collectio...	18 Years -	Memorial Sloan Kettering Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: